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Background: Growing evidence supports the possibility of significant psychiatric
consequences related to novel and traditional psychoactive substance consumption.
The problem of differential diagnosis has hampered research on specific
psychopathologies with unclear outcomes. The aim of our study was to report
psychiatric and clinical features of subjects admitted to a psychiatric ward in Ibiza,
Spain, with a clinical diagnosis of substance abuse or intoxication.
Methods: A survey was administered to a sample of inpatients hospitalized due to
psychiatric symptoms related to recent use of psychoactive substances. The
questionnaire investigated sociodemographic factors, familiar and personal anamnesis,
substance use habits, general and psychopathological features. Urine samples were
collected and analyzed in a toxicology laboratory using gas chromatography and
mass spectrometry.
Results: A total of 110 patients were included in the study. Most patients (70%) declared
multiple substance use, and 33% of patients reported more than two substances;
nevertheless, it was possible to identify 17 (15%) depressor users, 44 (40%) stimulant
users and 49 (45%) psychodysleptics users. A positive association with a lifetime
diagnosis of bipolar disorder was found (two-tailed Fisher’s exact test: p = 0.013).
Psychomotor agitation, reference, and paranoid delusions, affective symptoms,
consciousness disorders, and aggressiveness represented some of the most frequent
symptoms at entry evaluation.
Conclusions: In this study, we described the acute psychiatric presentations related to
recreational drug use in subjects on holiday in Ibiza. The use of psychoactive substancesg August 2020 | Volume 11 | Article 8791
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Frontiers in Psychiatry | www.frontiersin.orwas characterized by poly-use of both traditional and novel substances, with several
psychopathological consequences. Future research should focus on a better
understanding of the psychopathological effects of specific substances, defining signs
and symptoms to help make a differential diagnosis and prospectively examine long-term
effects.Keywords: club drugs, novel psychoactive substances, psychopathology, psychosis, substance use disorderBACKGROUND
Psychoactive substance use and related risks are considered a
worldwide major public health issue, involving a variety of health
and social consequences that require prompt sanitary policies as
well as constantly updated responses from health professionals to
promote harm reduction (1). In 2017, an estimated 271 million
people worldwide had used psychoactive substances during the
previous year—a number 30% higher than that in 2009 (2)—
putting substance use disorders (SUDs) among the leading causes
of disability worldwide (3). However, although consequences may
be dramatic in terms of morbidity, mortality, and psychiatric load,
such a widespread phenomenon is often defined as merely an
aberrant behavior by modern society.
As shown by recent trends, the extent of problematic drug use
is not limited to subjects with SUD or addiction; admissions to
specific clinical settings, such as Emergency Rooms (ERs) and
psychiatric wards, due to substance-related conditions involve a
heterogeneous cohort of users with different motivations of
intake. These range from traditional drug users to “psychonauts”,
clubgoers, students, athletes, marginalized populations, and
individuals with patterns of non-habitual recreational drug
consumption (4). Nevertheless, rates of SUD are significantly
higher (up to 50%) among psychiatric patients than in the
general population (5). In recent years, this rapidly evolving
scenario has been further complicated by the rise of novel
psychoactive substances (NPS). The United Nations Office on
Drugs and Crime reports define NPS as “substances of abuse,
either in a pure form or a preparation, that are not controlled by
the 1961 Single Convention on Narcotic Drugs or the 1971
Convention on Psychotropic Substances, but which may pose a
public health threat” (2). Many of these substances were originally
developed as research chemicals, as they often mimic the
pharmacological effect of traditional drugs of abuse, such as
cannabis or phenethylamines, and they were subsequently
repurposed for recreational use. NPS are formulated in a variety
of forms, both pure and in preparations with other substances.
When smoked, ingested, snorted, or injected they may produce a
plethora of psychotropic effects, of which some are not fully
described. This, along with their often-unknown toxicological
profile, their low traceability and the fast-moving and potentially
limitless nature of their online market, initially raised significant
concern among health professionals (6–8). Although a great effort
has been made in the last decade by the scientific community to
raise awareness and gain a better knowledge of such compounds
and their related risks (9), the understanding of various features,
including patterns of consumption, must be further developed (10).g 2Due to their diverse nature, various categorizations of NPS
have been proposed, according to their origin, chemical
structures or pharmacological action, among others. Based on
their clinical effects on the central nervous system, NPS can be
classified as stimulants, empathogens, entactogens, sedative-
hypnotics/anxiolytics, dissociatives, and hallucinogens (11). In
2019, the total number of NPS identified worldwide was over
950, of which the vast majority (almost 800 different compounds)
had been notified within the last decade (12). Although an
increasing number of studies report the potential acute and
chronic health dangers associated with such use, NPS and their
clinical effects and related risks are often unknown to both users
and health professionals, mainly due to a lack of evidence-based
sources of information and to the ever-changing nature of their
market (4, 9).
Nevertheless, growing evidence supports the possibility of
significant psychiatric and physical consequences related to NPS
consumption (13, 14). Recently, researchers have reported that
NPS consumption may be associated with the onset of a variety of
psychiatric symptoms and conditions, including confusion,
paranoid thoughts, auditory and visual hallucinations, dissociation
(e.g., derealization and somatopsychic depersonalization), insomnia,
chronic cognitive impairment and delusions of reference,
persecution, grandeur and jealousy, as well as hypomanic states,
aggressiveness and irritability, violence, and suicidal thoughts (15–
17). These symptoms are often due to the increased potency of NPS
compared to traditional substances, as well as to their action on a
number of different neural pathways, including dopamine (DA) and
serotonin (5-HT) receptors for psychedelic phenethylamines,
tryptamines and synthetic cathinones, cannabinoid (CB) receptors
for synthetic cannabinoids, and N-methyl-D-aspartate (NMDA)
receptors for some dissociatives (12). Such effects are particularly
alarming for compounds that are frequently sold and advertised as
natural and safer alternatives to other drugs. For example,
observational research on a cohort of 594 synthetic cannabinoids
users reported a higher prevalence of psychotic symptoms than in
cannabis users (18). Furthermore, the study showed that psychotic
disorders were usually more severe in synthetic cannabis users, and
patients required higher doses of antipsychotic medications and
were hospitalized for longer.
The growing prevalence of novel and traditional psychoactive
substances, and their related risks, is further complicated by the
phenomenon of “nightlife” and “clubbing” associated with
international travels. Holiday periods, particularly in summer,
appear to represent a time of risk, excess and experimentation,
especially among young people (19). Substance use is a
commonly reported habit among festivalgoers and clubgoers inAugust 2020 | Volume 11 | Article 879
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socially accepted and drugs are typically readily available—which
often involve practices such as polysubstance use (i.e., the
consumption of two or more compounds simultaneously) (20,
21). Several studies reported the detection in such contexts of a
variety of traditional drugs and NPS, such as synthetic cathinones,
synthetic cannabinoids, opioids, and naturally derived drugs (e.g.,
psilocybin, and ayahuasca), by using different screening
techniques that ranged from wastewater analysis to self-report
surveys (22–24).
Although virtually any psychoactive substance may be used in
such an environment for recreational purposes, the National
Institute on Drug Abuse (NIDA) includes six compounds among
the so-called “club drugs” or “rave drugs” (i.e., drugs commonly
consumed during electronic music festivals, dance parties or
raves from the 1970s to the present): flunitrazepam, ketamine, LSD,
methylenedioxymethamphetamine (MDMA), methamphetamine,
and gamma-hydroxybutyrate (GHB) (25). Users, especially young
subjects who are often unaware of health-related risks and of the
nature of such compounds, including potential contamination and
adulteration (26), seek positive effects such as euphoria, improved
psychomotor speed, alertness, sociability and talkativeness,
amplification of sensory perceptions, alteration of space and time
perception, loss of inhibition, increased libido, and improved sexual
performance (27–29).
The current dynamic drugs scenario raises enormous concerns
for public health at a national and international level. The risks
posed by club drugs and related phenomena require adequate
training for health professionals, effective harm reduction
interventions and updated policies provided by local and
supranational regulatory agencies (30). Addressing these
challenges may be crucial for guiding the diagnostic and
therapeutic options of healthcare professionals, as well as for
counteracting related psychiatric and physical risks, such as acute
toxicity. For this context, Ibiza and the Balearic Islands, one of the
most popular nightlife resorts for summer holidays in Europe,
appear as a crucial setting to explore psychopathological issues
related to both traditional drugs and NPS. Previous studies available
in literature confirmed a higher prevalence of risky behaviors for
both residents and tourists in Ibiza, including problematic alcohol
and substance use, and their connections with sexual disinhibition,
casual sexual relationships and unprotected sex (19, 31–33).
Furthermore, anecdotal cases of NPS intoxication have been
reported in recent years in the Ibiza drug market; in such a
dynamic setting, naive customers are frequently seen by traffickers
and dealers as test subjects for trialling new and potentially
dangerous compounds for the first time (33).
Our previous reports on this topic investigated substance-
related fatalities and provided a first insight of traditional drug-
and NPS-induced psychopathological symptoms, particularly
regarding aggressiveness (30, 33). The aim of the present study
was to analyze patients admitted to the psychiatric ward of the
CanMisses Hospital in Ibiza for psychoactive substance intoxication,
in order to (a) report the sociodemographic characteristics of the
sample, (b) identify which drug is most involved; (c) assess
psychopathological features associated with substance use,Frontiers in Psychiatry | www.frontiersin.org 3particularly regarding psychotic symptoms (referring to bipolar or
schizophrenic spectrum disorder) and behavioral disturbances.MATERIAL AND METHODS
Patient Recruitment
Subjects admitted to the Can Misses Hospital psychiatry ward
during the summer nightclub opening periods between May
2015 and October 2018 were recruited for the study. This sample
was derived from a larger sample of 223 subjects transferred to
hospital ER from discotheques and other clubs around the island
who were exhibiting intoxication and/or manifestations of
psychiatric interest. All patients were evaluated according to
the DSM-5 diagnostic classification. Inclusion criteria were being
aged between 18 and 75 years and reporting the intake of
psychoactive substances or more than five units of alcohol over
the previous 24 hours. Patients with delirium tremens, epilepsy, liver
encephalopathy, dementia and other neurological diseases, severe
cardiac failure, diabetes mellitus, severe liver impairment, kidney
failure, or neoplastic diseases were excluded after clinical evaluation.
Data Collection
Demographic (age, gender, family, and nationality) and socioeconomic
data (living status, job status, and level of education) were collected in a
structured interview administered during hospitalization, after the
resolution of intoxication symptoms. The interview investigated
recent and past medical and psychiatric history in addition to
alcohol and substance use habits (tobacco, caffeine, cannabis, cocaine,
and heroin), with a focus onNPS. Among these, recent and lifetime use
of synthetic cannabinoids, synthetic cathinones [e.g., mephedrone,
methylone, methylenedioxypyrovalerone (MDPV), alpha-
pyrrolidinopentiophenone (a-PVP)], amphetamine and
methamphetamine, plant-based substances (e.g., ayahuasca, kratom,
Salvia divinorum), GHB and GBL (g-butyrolactone), dissociative
substances (e.g., ketamine and methoxetamine), and psychedelics
(e.g., LSD, magic mushrooms) was investigated. Misuse of
prescription drugs such as benzodiazepines, methylphenidate, and
opioid painkillers was also explored. A urine sample was collected
upon admission, stored at −30°C and subsequently analyzed at the
laboratory of either the Department of Forensic Toxicology of the
Università Politecnica delle Marche, Italy, or the National Institute of
Toxicology and Forensic Sciences in Barcelona, Spain. Gas
chromatography/mass spectrometry (GC/MS) was used to confirm
the consumption of psychoactive substances and/or prescription drugs.
Psychodiagnostic Tests and Analysis
The following psychodiagnostic tests were administered to
patients during their hospitalization: Timeline follow-back for
psychoactive substances and alcohol (TLFB); Positive and
Negative Symptoms Scale (PANSS); Brief Psychiatric Rating
Scale (BPRS); Mania Rating Scale (MRS); Hamilton Depression
Scale (HAM-D); Hamilton Anxiety Scale (HAM-A); Modified
Overt Aggression Scale (MOAS). TLFB was used to identify the
main substance of abuse for each patient. The other psychometricsAugust 2020 | Volume 11 | Article 879
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depressive or manic symptoms, anxiety, psychosis negative or
positive symptoms, somatic disorders, aggressiveness, and
suicidality. The choice of psychometric instruments was derived
from our previous studies on the topic (4, 33). Patients were divided
into three main substance macro-categories according to the TLFB
and the results of the urine analysis: Psychostimulants (e.g., cocaine,
amphetamines, and synthetic cathinones), Psychodepressors (e.g.,
opioids, alcohol, and benzodiazepines) and Psychodysleptics (e.g.,
cannabinoids, psychedelics, dissociatives, empathogens, and
entactogens). This classification was derived from our previous
reports on the topic (4, 33). According to their pharmacological
profiles (11), patients were also allocated to a specific group:
Opioids, Stimulants, Empathogens-Entactogens, Psychedelics,
Dissociatives, Cannabinoids, and Depressors. Urinalysis was
performed in two separate laboratories (to enhance the level of
sensitivity and specificity).
Ethics
Data collection was carried out anonymously and confidentially;
all participants received a detailed explanation of the design of
the study and written informed consent was systematically
obtained from every subject, according to the Declaration of
Helsinki. Ethical approval was granted by the University of
Hertfordshire Health and Human Sciences ECDA, protocol no.
aPHAEC1042(03); by the CEI Illes Balears, protocol no. IB 2561/
15 PI (“Estimación y Evaluación de sıńtomas inducidos por
Sustancias y Alcohol”, Dr.a Cristina Merino del Villar, Area de
Salud Mental de Eivissa y Formentera); and by the University
“G.d’Annunzio” of Chieti-Pescara, no. 7/09 04-2015.
Data Analysis
Statistical analysis was performed by using IBM SPSS® Statistics
software, version 20 and GraphPad 5.0 software for Windows (La
Jolla, CA, USA). Independence between substance use and
psychiatric diagnosis, as well as between substance use and
symptoms at admission, was analyzed using a two-tailed Fisher’s
exact test. Correlation between substance categories or groups and
psychiatric scales scores was analyzed by linear regression. Data
concerning scale scores according to categories and groups of
substances were analyzed by one-way analysis of variance
(ANOVA), followed by Tukey’s post hoc test. For all tests, a p
value of <0.05 was considered statistically significant.RESULTS
Sociodemographic Data
A total of 223 subjects showing a condition of intoxication and/
or manifestation of psychiatric interest were transferred to the
hospital ER from discotheques and other clubs around the island.
Of this sample, 110 (49.3%) required subsequent psychiatric
hospitalization and were enrolled in the study, whereas 50.7% of
the sample only required a 2- to 36-hours stay in the emergency
department before a rapid discharge. Sociodemographic information
for the sample is reported in Table 1.Frontiers in Psychiatry | www.frontiersin.org 4Categories and Groups of Abused
Substances
All the subjects of the sample were diagnosed with substance
intoxication at admission. Although the majority of patients
declared multiple substance use (n = 77, 70.0%) and 33% of
them reported more than two substance use, participants were
divided into three macro groups according to their responses to
the TLFB test and to the urinalysis in order to identify a category
of substances “of choice” for each patient. This allowed to identify
17 (15%) depressors users, 44 (40%) stimulant users and 49 (45%)
psychodysleptics users. When asked about lifetime use of specific
groups of substances, stimulant use was disclosed by 74 patients
and cannabis use by 68 patients. Categories of substances
according to the TLFB and urinalysis, as well as prevalence for
each substance group, are listed in Table 2. Cannabis and
cannabinoids (40%) were the most common substances among
patients who declared the use of only a single type of drug.TABLE 1 | Sociodemographic characteristics of the sample.
Characteristic n %
Sample size 110 100
Gender
Male
Female
76
34
69.1
30.9
Nationality
European
Other
Not available (NA)
79
30
1
71.8
27.3
0.9
Education level
Primary education
Secondary education
Higher education/undergraduate
Higher education/postgraduate
NA
9
18
42
19
22
8.2
16.3
38.2
17.3
20.0
Working status
Worker/professional
Student
Student and worker
Unemployed
Retired
NA
52
6
3
40
1
8
47.3
5.4
2.7
36.4
0.9
7.3
Marital status
Single/never married
Divorced
Married
NA
66
21
13
10
60.0
19.1
11.8
9.1
Living status
With parents
With a partner
Alone
With partner and child/children
With friends/flatmates
Other
NA
29
22
27
13
10
2
7
26.4
20.0
24.5
11.8
9.1
1.8
6.4
Age subgroups
<30 years old
31–50 years old
>50 years old
57
47
6
51.8
42.7
5.5
Range (years) Mean
(SD)
Age 19–63 32.57 (9.15)
Total years of education 5–27 12.91 (4.48)August 2020 | Volume 11 | Article 879
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agitation, which was observed in 43 patients, followed by
reference ideation (n = 36) and paranoid delusional ideation
(n = 30). Physical restraint was necessary for 14 patients (4%) in
order to control symptoms (e.g., aggressiveness with concrete
risk of harm to self or others). A detailed overview of symptoms
detected upon evaluation in the ER is displayed in Table 3. The
distribution of symptoms according to categories and specific
groups of substances is highlighted in Figure 1.
A large majority of patients in our sample (83%, n = 91)
reported to have a previous psychiatric history: 31% had received
only one DSM-5 diagnosis, 30% had received two, 22% had
received three, 14% had received four and 3% had received more
than four. Among those who had previously received only one
diagnosis according to DSM-5 criteria, bipolar disorder (21%),
and psychotic episode (32%) were the most common. The
psychiatric diagnoses associated with each group and category
of substances are shown in Figure 2.
We investigated possible associations between psychoactive
substance use and specific psychiatric diagnoses. In particular,
we found a positive association between psychoactive substance
use and lifetime diagnosis of bipolar disorder (two-tailed Fisher’s
exact test p = 0.013). Unsurprisingly, a positive correlation with a
previous diagnosis of SUD was also reported (two-tailed Fisher’s
exact test p = 0.003). No significant association betweenFrontiers in Psychiatry | www.frontiersin.org 5substance use and the other psychiatric diagnoses was found
(two-tailed Fisher’s exact test p > 0.05).
Positive associations were also found with temporal
disorientation at admission (two-tailed Fisher’s exact test p =
0.022), although data were available for only 63 patients. No
significant association between substance use and any other
symptom at admission was found (two-tailed Fisher’s exact test
p > 0.05).
Substance Use and Psychodiagnostics
Scales
Severity of anxiety and depression symptoms according to
HAM-A and HAM-D scales were comparable among different
substance categories. The distribution of scores on the
aforementioned scales is available in Figure 3.
Similarly, scores on the PANNS positive and negative
subscales and total scores were equally distributed among
categories of substances, as shown in Figure 4.
Presence and severity of mania and associated symptoms
according to MRS were comparable among the different
categories of substances. Finally, for general psychiatric symptoms
assessed with the BPRS, no significant differences were found
among depressor, stimulant and psychodysleptics users (Figure 5).
Severity of psychiatric symptoms according to HAM-D,
HAM-A, BPRS, and MRS were comparable among specific
groups of substances. However, it was possible to highlight a
higher prevalence of psychotic symptoms, according to the
PANSS Positive Scale, for psychedelic substances users
compared to opioid users (Figure 6B).
Results of the linear regression analysis highlighted a weak
positive correlation between psychedelics use and PANNS Positive
Symptoms scores (R = 0.374) and BPRS scores (R = 0.324), as well
as between depressors use and BPRS scores (R = 0.322).
Diagnoses Recorded at Discharge
Among the 110 participants, the most common psychiatric
diagnosis at discharge was SUD (n = 44), followed by psychotic
episode (n = 29). The main diagnoses assigned to patients after
dismission from the psychiatric ward are described in Table 4.DISCUSSION
In this study, we described the acute psychiatric presentations
related to recreational drug use in an adult population of subjects
on holiday in Ibiza. This region has the highest number of nights
spent by EU residents in tourist accommodation establishments
(34) and has a flourishing “substance market”, which is
frequently updated with newly developed recreational drugs.
The characteristics of our sample, with high levels of education
and good employment rates, differ from the typical profile of a
substance abuser (35). An explanation for this phenomenon
might be that the characteristics of substance-using clients
have changed over recent years. In particular, clubbers and
recreational drug users differ greatly from the “drug addicts” of
the past (3, 36, 37). Moreover, Ibiza is a peculiar scenario inTABLE 2 | Categories and groups of abused substances.
Categories n %
Psychodysleptics 49 45
Psychostimulants 44 40
Psychodepressors 17 15
Groups
n %
Stimulants 74 32
Cannabinoids 68 29
Depressors 32 14
Empathogens-Entactogens 28 12
Dissociatives 15 6
Opioids 9 4
Psychedelics 7 3TABLE 3 | Symptoms observed at admission.
Entry Evaluation n %
Spatial disorientation 17 5
Temporal disorientation 23 7
Paranoid delusional ideation 30 9
Mystic delusional ideation 8 3
Reference delusional ideation 36 11
Grandeur delusional ideation 22 7
Mood elevation 21 7
Mood lowering 22 7
Psychomotor agitation 43 13
Sexual disinhibition 11 3
Anxiety and somatic anxiety 24 8
Aggressiveness towards others 24 8
Self-harm behaviour 14 4
Suicidality 25 8August 2020 | Volume 11 | Article 879
Martinotti et al. Club Drugs and Psychopathologywhich subjects from low-income classes may not be able to find
affordable facilities, while on the other hand, young tourists
choose to spend most of their money earned during the
winter period.
Cannabis and cocaine (in its different formulations, including
crack) reported by users in the TLFB and by the urinalysis, were
the most commonly referred substances, along with the presence
of other traditional substances such as opiates, psychedelics, and
entactogens. Alcohol was also commonly reported, mainly in
association with other molecules. These findings have been
confirmed by other studies that have demonstrated that most
common emergency presentations related to acute recreational
drug toxicity were associated with cocaine and cannabis use (38).
NPSs represent a limited proportion (20%) of those reported.
This data is of some interest, given that this is a real-life sample
composed mostly of holidaymakers, among whom “2.0 online
psychonauts” (39) do not represent the classical phenotype.
Polysubstance abuse, including the use of two to six differentFrontiers in Psychiatry | www.frontiersin.org 6substances during the same night, with alcohol as the substance
most involved, followed by cannabis and cocaine, was showed to
be a common behavior. The combination of psychoactive drugs
may have numerous health implications (33, 40) and has been
linked to increased levels of intoxication and possible fatality
(41). Therefore, although a main “preferred” substance could be
frequently identified with the structured interview and urinalysis
data, the presence of polysubstance abuse appeared to be the
relative norm.
Regarding the psychopathological evaluation upon admission,
it is interesting to note the presence of spatial and temporal
disorganization—an indication of qualitative alteration of
consciousness. This phenomenon was evidenced mainly among
users of psychostimulants and psychodysleptics. These types of
manifestations are typical of the twilight state already described in
SUDs (42) and are characterized by a state of clouded
consciousness in which the individual is temporarily unaware of
his or her surroundings. Our study confirms the importance of aA
B
FIGURE 1 | Entry evaluation distribution according to groups and categories of substances. (A) Entry evaluation distribution according to the following groups of
substances: opioids, stimulants, empathogens-entactogens, psychedelics, dissociatives, cannabinoids, and depressors. (B) Entry evaluation distribution according to
the following categories of substances: psychodepressors, psychostimulants, and psychodyslpetics.August 2020 | Volume 11 | Article 879
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FIGURE 3 | Hamilton Depression (HAM-D) and Anxiety (HAM-A total) scales scores according to categories of substances. (A) HAM-D scale score according to the
following categories of substances: psychodepressors, psychostimulants, and psychodyslpetics. (B) HAM-A total scale score according to the following categories
of substances: psychodepressors, psychostimulants, and psychodyslpetics.A
B
FIGURE 2 | Categories and groups of substances and last diagnosis according to DSM-V. (A) Last DSM-V diagnosis distribution according to the following groups
of substances: opioids, stimulants, empathogens-entactogens, psychedelics, dissociatives, cannabinoids, and depressors. (B) Last DSM-V diagnosis distribution
according to the following categories of substances: psychodepressors, psychostimulants, and psychodyslpetics.Frontiers in Psychiatry | www.frontiersin.org August 2020 | Volume 11 | Article 8797
Martinotti et al. Club Drugs and Psychopathologycorrect assessment of the patient’s state of consciousness. These
transient cognitive disorders are quite unusual in psychiatric
illnesses, with the exception of dissociative disorders, frequentlyFrontiers in Psychiatry | www.frontiersin.org 8described in the literature as substance-induced symptoms (43).
The qualitative alterations of consciousness could, in fact, be
characterized as distinguishing elements between a classicA B
C
FIGURE 4 | Positive and Negative Syndrome Scale (PANSS) positive, negative, and total scores according to categories of substances. (A) PANSS positive score
according to the following categories of substances: psychodepressors, psychostimulants, and psychodyslpetics. (B) PANSS negative score according to the
following categories of substances: psychodepressors, psychostimulants, and psychodyslpetics. (C) PANSS total score according to the following categories of
substances: psychodepressors, psychostimulants, and psychodyslpetics.A B
FIGURE 5 | Mania Rating Scale (MRS) and Brief Psychiatric Rating Scale (BPRS) scores according to categories of substances. (A) MRS score according to the
following categories of substances: psychodepressors, psychostimulants, and psychodyslpetics. (B) BPRS score according to the following categories of
substances: psychodepressors, psychostimulants, and psychodyslpetics.August 2020 | Volume 11 | Article 879
Martinotti et al. Club Drugs and Psychopathologypsychotic episode and an episode induced by substances.
Moreover, it could become a predisposing factor facilitating the
development of delusional thoughts. Among the other
phenomena found in the initial evaluation of the patients, theFrontiers in Psychiatry | www.frontiersin.org 9presence of psychomotor agitation, aggression, self-harm
and suicidality stand out, specifically in the group of
psychodysleptics and psychostimulant users. This data still
emphasizes that this type of patient represents a category at
risk, also in terms of public health, as recently reported in other
studies (44, 45). Reference and paranoid delusions were the most
commonly described delusional phenomena, specifically in the
category of psychostimulants and psychodysleptics users, in
accordance with the literature (46). The substance- or alcohol-
induced delirium is often characterized by confirmation and
interpretation, rather than by revelation, and by imaginative
contents. The delusions reported are similar to paraphrenic
delusions, with a feeling of unreality, while the ability to analyze
the feeling is preserved. In this regard, the model of the Lysergic
Psychoma could be an interesting proposal (14). As already
highlighted by previous studies (47), relevant symptoms were
also inherent to the sphere of affectivity, both in the direction of
positive and negative polarity. This data confirms how substance-
induced phenomena often have a significant affective componentA B
C
FIGURE 6 | Hamilton Depression (HAM-D) Scale, Positive Syndrome Scale (PANSS), and Brief Psychiatric Rating Scale (BPRS) scores according to groups of
substances. (A) HAM-D scale score according to the following groups of substances: opioids, stimulants, empathogens-entactogens, psychedelics, dissociatives,
cannabinoids, and depressors. (B) PANSS positive score according to the following groups of substances: opioids, stimulants, empathogens-entactogens,
psychedelics, dissociatives, cannabinoids, and depressors; *p < 0.05. (C) BPRS score according to the following groups of substances: opioids, stimulants,
empathogens-entactogens, psychedelics, dissociatives, cannabinoids, and depressors.TABLE 4 | Discharge diagnoses.
Discharge Diagnosis N %
Bipolar disorder 9 6
Psychotic episode 29 19
Cluster B personality disorder 13 8
Substance use disorder 44 28
Alcohol abuse 16 10
Paranoid schizophrenia 4 2
Schizoaffective disorder 1 1
Manic Episode 9 6
Depression 6 4
Behavior Disorder 18 12
Adjustment Disorder 3 2
Anxiety Disorder 3 2August 2020 | Volume 11 | Article 879
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dopaminergic and serotonergic systems (48).
Among the psychiatric manifestations observed in our
sample, psychotic and mood symptoms predominated. Our
findings have been confirmed by Acciavatti et al., who
evidenced bipolar disorder and schizophrenia as the main
psychiatric diagnostic frameworks within which the use of
psychoactive substances is reported (47). Specifically, our study
showed a significant association between a previous diagnosis of
bipolar disorder and the use of substances. As regards the
presence of the different diagnostic frameworks according to
DSM-5 and the different types of substances, it should be
emphasized that in the group of subjects with a diagnosis of
schizophrenic spectrum disorder, a substantial number of
subjects reported the use of entactogens/empathogens
substances and dissociatives. This issue should be further
investigated in future studies, given its relevance in terms of
possible preventive strategies. Other diagnostic frameworks of
greater response were those of depressive disorders, widely
distributed among users of depressors and opiates, that of
cluster B personality disorders, anxiety disorders, ADHD and
eating behavior disorders. These data are in agreement with
other studies in the literature with similar cases of substance
abuse patients (49–51).
Mean scores of psychodiagnostic scales showed that
psychiatric manifestations linked to psychoactive substances
are characterized by a globally high level of psychopathology.
As expected, PANSS Positive mean scores were higher than
PANSS Negative mean scores, which is consistent with previous
reports: a 2016 study demonstrated that patients with substance-
induced psychosis had similar PANSS positive and significantly
lower PANSS negative scores than patients with schizophrenia
(4, 52). This data shows that the psychopathological potential of
recreational substances is considerable, also in subjects without
previous psychiatric symptoms of clinical relevance. We
hypothesized that specific high potency substances, considerable
amounts of a substance, and a high frequency of use may represent
trigger factors. By differentiating between the groups of substances,
it was possible to highlight how the use of psychedelics, compared
to that of opiates, was more strongly associated with the presence of
positive symptoms for PANSS. This data confirms that opiates can
have an antipsychotic potential, or in any case, represent a group of
substances with a low potential to induce positive symptoms (53).
In relation to the results for the other psychopathological scales
of depression, anxiety, and mania, there is also evidence of high
score levels. However, no significant differences are observed
between the different groups (Opioids, Stimulants, Empathogens-
Entactogens, Psychedelics, Dissociatives, Cannabinoids, and
Depressors) or between the different categories of substances
(Psychostimulants, Psychodysleptics, and Psychodepressors). This
result could be explained by the high prevalence of poly-abuse,
described in the majority of patients evaluated and also involving
more than four substances together during the same night. For this
reason, it is credible that possible intrinsic differences, with respect
to the mechanism of action of the individual substances, have not
resulted in fully manifesting themselves and, therefore, have notFrontiers in Psychiatry | www.frontiersin.org 10reached specific significance levels. If, on the one hand, this result
may appear unsatisfactory, on the other, it should be emphasized
that it represents a real-life population of abusers, in which the
presence of a mono-substance user, always faithful to a single type
of drug, represents an ideal scenario. This may also represent an
important groundwork for harm reduction and prevention policies.
It is interesting to note the disparity between the diagnoses at
discharge and the acute symptoms that have been observed upon
admission. This data demonstrates how the psychoactive
substance-induced phenomena often act as confounding factors
for a correct diagnosis. At discharge from the hospital, the
diagnosis of psychotic episode was reported in more than half of
the participants. However, such a diagnosis is of an unclear nature,
mostly in terms of future developments. Another relevant area of
diagnosis was that of mood disorders (54% of the sample), with
manic episodes in a high percentage of cases. Also, at discharge,
multiple diagnoses still coexist, confirming the complexity of
the field.
Limitations of the Study
This study presents limitations: 1) the possibility to identify new
substances in urine samples remains both complex and limited,
which also applies to post-mortem samples. We performed a
professional urine drug screening but the comparison between
the self-report and objective data is still far from being considered
reliable; 2) in our analysis, we did not consider the intoxication cases
managed at the emergency department and not admitted to the
psychiatry unit. With this bias, we have probably excluded from our
evaluation those subjects with acute and rapidly transient psychiatric
reactions; 3) the long-term effects of novel and traditional substances
are still a matter of discussion and are difficult to assess without
follow-up examinations; and 4) differentiation according to groups
(Opioids, Stimulants, Empathogens-Entactogens, Psychedelics,
Dissociatives, Cannabinoids, and Depressors) and categories
(Psychostimulants, Psychodysleptics, and Psychodepressors) is
probably not ideal, as multiple substance abuse was the
predominant behavior.
In future studies, the following points shall be addressed: 1) to
better discriminate the psychopathological effects of specific
substances, including NPS and select a common ground able
to help in differential diagnosis, 2) to prospectively look at the
long-term effects, 3) to retrospectively observe which pharmacological
treatments show higher levels of effectiveness.CONCLUSIONS
In a sample of subjects admitted to a psychiatric ward in a
nightlife resort area, the use of psychoactive substances was
notable and characterized by poly-use of both traditional and
novel substances, with a relevant number of complex
psychopathological consequences. Positive and manic symptoms
and aggressiveness, including self-harm and suicidality, were
highly represented, as well as state-of-consciousness alterations.
These symptoms were not always transient in their nature and
sometimes difficult to categorize via psychiatric diagnoses builtAugust 2020 | Volume 11 | Article 879
Martinotti et al. Club Drugs and Psychopathologypredominantly for subjects without current use of substances. All
of the above-mentioned considerations should be investigated in
further studies, together with careful monitoring of critical
“hotspots” of substance misuse, in order to design better and
targeted prevention strategies.DATA AVAILABILITY STATEMENT
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